Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi-centre retrospective analysis of 105 R/R CLL patients who received venetoclax preNational Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1-15). 48% had TP53 disruption. At ≥2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3-kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no prior BTKi, and 10% received both. Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [CR]). The overall response rate was 85% (CR 23%) in BTKiexposed patients, 92% (CR 38%) in Pi3Ki-exposed patients and 80% (CR 20%) in both (P = 0Á59). With a median follow-up of 15Á6 months, 1-year progression-free survival was 65Á0% and 1-year overall survival was 75Á1%. Dose reduction or temporary interruption did not result in an inferior progression-free or discontinuation-free survival. Risk of progression or death after stopping a prior BCRi for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2Á01 P = 0Á05). Venetoclax is active and well tolerated in R/R CLL post ≥1 BCRi. Reason(s) for stopping BCRi influences venetoclax outcomes.
The therapeutic landscape for patients with chronic lymphocytic leukaemia (CLL) has undergone transformative changes over recent years, particularly with the advent of novel kinase inhibitors targeting Bruton tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K), disrupting signalling downstream of the B cell receptor (BCR) pathway. Ibrutinib monotherapy and Idelalisib alongside rituximab represent modern standard of care options in patients with relapsed CLL following respective phase III trials displaying an overall survival benefit versus anti-CD20 monoclonal antibody monotherapy (Byrd et al, 2013; Furman et al, 2014) .
Although many patients achieve durable remissions on either agent, there are no plateaus noted on progression-free survival (PFS) analyses and, as such, patients receiving either agent will continue to relapse on therapy. Relapse may occur earlier in patients with TP53 disruption (TP53 deletion and/ or TP53 mutation) and/or complex karyotype (Byrd et al, 2015) . Accumulating evidence suggests that many BCR inhibitor (BCRi)-treated patients outside of the clinical trial setting discontinue BTK and Pi3K inhibitors due to intolerable toxicity. For example, a recently published retrospective series reported that of 621 patients treated with ibrutinib (536 relapsed-refractory [R/R] and 80 treatment-na€ ıve), 42% had discontinued ibrutinib at a median of 7 months. Toxicity was the dominant cause of discontinuation in both previously treatment-na€ ıve patients (63Á1%) and R/R patients (50Á2%) (Mato et al, 2018a) . Idelalisib has a well described toxicity prolife including a considerable burden of intolerable adverse events (AEs) and treatment discontinuation (Mato et al, 2017a) .
In light of these data, effective, non-toxic therapy in the post-BCRi setting has become a focus of clinical need. Venetoclax is a potent, selective and orally bioavailable smallmolecule inhibitor of the anti-apoptotic protein BCL2, with demonstrable activity in patients with R/R CLL, including TP53-disrupted disease. Two phase II trials demonstrate impressive activity in these settings with an overall response rate (ORR) of approximately 80% in the BCRi-na€ ıve setting (Roberts et al, 2015; Stilgenbauer et al, 2016) . As a result, venetoclax was approved in the European Union for adults with TP53-disrupted CLL who are either unsuitable for, or have failed a BCRi and for those without TP53 disruption who have failed both chemo-immunotherapy and a BCRi. (http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/004106/WC500218800. pdf).
Recent data have established the clear activity of venetoclax post-BCRi. Jones et al (2017) demonstrated an ORR of 65% following ibrutinib (n = 91) with a median PFS of 24Á7 months (95% confidence interval [CI] 19Á2-not reached [NR] ), and estimated 12-month PFS of 75% (95% CI 64-83%). A separate cohort in the same trial recently reported an ORR of 67% in 36 patients who received idelalisib as their last BCRi pre-enrolment. For these patients, the median PFS had not yet been reached and estimated 12-month PFS was 79% (Coutre et al, 2018) . Results from a small cohort Venetoclax Efficacy in Relapsed, Refractory CLL ª 2019 British Society for Haematology and John Wiley & Sons Ltd within the trial of heavily pre-treated, dual BCRi exposed patients (n = 28) were recently reported, with a lower ORR of 39% (Wierda et al, 2017a) .
In a recent published series, Mato et al (2018b) presented data from a separate US cohort outlining venetoclax monotherapy efficacy in 141 patients, of which 89% had been exposed to a BCRi. Patients had received 3 prior lines and 45% had 17p deletion. The ORR was 72% (complete response [CR] 19Á4%) and with a short median follow-up of 7 months, the median PFS and overall survival (OS) was not reached. The projected 12-month PFS and OS was 68% and 88%, respectively. Mato et al (2017b) provided the largest real world data (RWD) sets of venetoclax monotherapy in relapsed CLL. Most of the 204 patients across US and international community and academic centres successfully completed the dose ramp-up and maintained a maximum dose of 400 mg o.d. Toxicity was manageable, and it was CLL progressive disease (PD) (47%), not toxicity (11%) that lead to most venetoclax discontinuation. The ORR was 77% (28% CR) and the median PFS and OS were not reached. In this series, only 63% were exposed to BCRi and no minimal residual disease (MRD) data were presented. Venetoclax was active in patients resistant to ibrutinib although patients with prior ibrutinib exposure and poor risk cytogenetics were associated with an inferior PFS.
It is clear that venetoclax is an effective agent in high-risk R/R CLL, including patients previously exposed to BCRi therapy. However, for the published RWD data, the median follow-up is short, there is a lack of MRD response data on venetoclax and a lack of information on the impact of patient performance status (PS) on outcome.
In light of the high incidence of BCRi discontinuation in the non-trial setting (Mato et al, 2018a) , and the demonstrable efficacy of venetoclax in the post-BCRi setting, we wished to analyse the early experience of venetoclax monotherapy in routine practice. Venetoclax was available free-of-charge to named UK and Irish patients from 2015, initially prior to European Medicines Agency (EMA) approval via a named-patient scheme and subsequently through the early access to medicine scheme prior to National Health Service (NHS) commissioning. Thus, a defined consecutive cohort of patients was available for evaluation, representing early experience of venetoclax monotherapy in routine clinical practice.
Material and methods
The UK CLL Forum invited UK clinicians to contribute data on patients with R/R CLL, treated with venetoclax within the named-patient schemes from August 2015 to November 2017. Patient data from 44 participating centres were collected using a pre-specified extraction sheet including details on: baseline characteristics; duration of first remission; number of prior lines of therapy; TP53 status prior to venetoclax; duration of prior BCRi and reasons for BCRi discontinuation; histological transformation events; objective response per International Workshop on CLL (iwCLL) criteria ; and use of rasburicase. For AE data, given the nature of the study, we focused on elective and unplanned hospitalisations, infection episodes, tumour lysis syndrome (TLS) events, dose interruptions and permanent discontinuation. TLS events were defined according to the Howard criteria, which specify criteria for laboratory and clinical TLS (Howard et al, 2011) . Follow-up was censored at the most recent hospital visit or death. The database was locked in August 2018 for analysis.
PFS was defined as the time from the start of venetoclax until PD or death from any cause, discontinuation-free survival (DFS) was defined as the time from the start of venetoclax until discontinuation or death, and OS was defined as the time from start of venetoclax to time of death from any cause. Duration of response (DOR) was measured from the date of best response until PD date. Patients who died of unrelated causes were censored at death. Survival analyses were calculated in standard fashion by Kaplan-Meier analysis (Kaplan & Meier, 1958 ). Univariable and multivariable Cox regression was used to examine the associations between baseline factors, PFS and OS (Cox, 1972) . Chi squared or Fisher's exact tests were used to compare ORR rates between different baseline groups. Statistical analyses were performed in STATA 15.1 (StataCorp, College Station, TX, USA).
Patients were treated with venetoclax in line with the EMA label, employing the now established weekly ramp-up phase from 20 mg o.d. to 400 mg o.d., and typically received monotherapy until PD, toxicity or death. Data on any additional therapies given alongside venetoclax (indicated, for example, for autoimmune phenomena), including anti-CD20 monoclonal antibody therapy, were also collected.
Patients were assessed by their treating clinician according to the iwCLL criteria , although bone marrow biopsies and computed tomography imaging was not uniformly undertaken given the nature of this RWD collection. Data on MRD evaluation by flow cytometry of peripheral blood (as per the European Research Initiative on CLL consensus recommendations) (Rawstron et al, 2018) were collected where available.
Results
We present data on 105 patients who commenced venetoclax between August 2015 and November 2017. The median age was 67 years (range 39-87) with a predominance of males (73% male, 27% female) ( Table I) . Patients had received a median of 3 prior lines of therapy (range 1-15 lines). Prior to venetoclax, the Eastern Cooperative Oncology Group performance status (ECOG PS) was 0-1 in 74% (78/105) and 2-3 in 26% (27/105). Forty-eight percent of patients had evidence of TP53 disruption defined by either a TP53 deletion 
Duration of prior BTKi (n = 73) (median and range in months)
Duration of prior Pi3Ki (n = 36)* (median and range in months)
Duration of prior BCRi (n = 109)* (median and range in months) At second or subsequent line of therapy, 60% (62/104) of patients had received ibrutinib or another BTK inhibitor (BTKi) and no prior Pi3K inhibitor (Pi3Ki), 25% (26/104) of patients had received idelalisib or another Pi3Ki (duvelisib; n = 1) and no prior BTKi, 10% (10/105) had received both a prior BTKi and Pi3Ki (Table I) . Tirabrutinib was the only other BTKi used (n = 2). One patient may have previously been exposed to idelalisib within a blinded randomised trial (excluded from all BCRi analyses). Only 6% (6/105) patients were BCRi-naive.
Patients had discontinued BCRi therapy because of toxicity in 44% (48/109 total BCRi treatment lines) and PD in 54% (59/109 treatment lines). According to BCRi subgroup, 36% (27/73) stopped BTKi due to toxicity and 64% (46/73) due to PD whilst 58% (21/36) stopped PI3Ki due to toxicity and 36% (13/36) due to PD. Two (2%) patients stopped PI3Ki with responsive disease with the clinician's intention of achieving a deeper response prior to allogenic stem cell transplantation (alloSCT). The median duration of BTKi and PI3Ki therapy was 15 (range 0Á25-48) months and 8Á5 (range 1-27) months, respectively. The median interval from BTKi and PI3Ki discontinuation to starting venetoclax was 50 (range À2 to 976) days and 125 (range 0-837) days respectively.
Additional therapy received alongside venetoclax was noted in 15% (16/105) patients and included rituximab (n = 7), steroids (n = 5), obinutuzumab (n = 1), ibrutinib (n = 1), both rituximab and steroids (n = 1) and unknown (n = 1).
By pre-defined criteria (https://www.venclextahcp.com/ve nclexta-dosing-regimen/tumor-lysis-syndrome-risk-assessme nt.html), the TLS risk was low, intermediate or high in 27% (28/105), 25% (26/105) and 48% (50/105) patients respectively (Table I) . TLS risk was not classified in 1 patient. Seventy-two percent (73/102) of patients received ≥1 dose of rasburicase as TLS prophylaxis. Overall, patients received a median of 2 doses of rasburicase (range 0-17) and were electively admitted to an inpatient bed for a median of 1 (range 0-6) occasion(s). Sixty-two percent (65/105) of the cohort were elective admitted during dose escalation at least on 1 occasion. The ORR in patients who received a prior BTKi was 85% (CR 23%, PR 62%), a prior Pi3Ki was 92% (CR 38%, PR 54%) and 80% (CR 20%, PR 60%) for the 10 patients who were previously exposed to both BCRi classes. All 6 BCRina€ ıve patients responded (ORR 100%) with 5 (83%) documented CRs (Table II , Fisher's exact P = 0Á59 for ORR comparing the four groups). The ORR in patients without TP53-disruption was 89% (CR 28%, PR 61%), and 86% (CR 32%, PR 54%) for those with TP53 disruption (Chi-squared, P = 0Á68).
Response rates and survival outcomes
The median PFS was not reached, with a 1-year PFS of 65Á0% (95% CI 54Á7-73Á6) and 60Á9% (95% CI 50Á1-70Á0) at the median follow-up of 15Á6 months. The median OS was 21Á1 months, a 1-year OS 75Á1% (95% CI 65Á4-82Á5) and 69Á5% (95% CI 58Á9-77Á9) at the median follow-up of 15Á6 months (Fig 1A,B) .
Duration of response
The time to best ORR in the 92 responsive patients was 3Á7 months (range 0Á7-18Á1 months) with a median DOR not reached and 75Á4% (range 62Á0-84Á7) of patients achieving a DOR of 1 year or greater. The median time to PR as best response was 3Á4 months (range 0Á2-14Á8) and CR as best response was 4Á5 months (range 0Á7-18Á1). Of those patients obtaining a PR, 64Á8% (95% CI 44Á9-79Á0) had a DOR of 1 year compared to 91Á8% (95% CI 70Á9-97Á9%) at 1 year for those reaching CR (Fig 2A) . Patients responding to venetoclax experienced a longer survival than non-responders. Notably, the depth of response influenced OS; patients achieving CR experienced a superior OS compared to patients achieving PR. OS at 6 months for patients achieving CR was 100%, PR 83Á8% (95% CI 71Á1-78Á5), SD 25% (95% CI 8Á9-66Á5) and PD 22% (95% CI 3Á4-51Á3).
The PFS rate at 12 months for complete responders was 95Á7% (95% CI 72Á9-99Á4) and 66Á4% (95% CI 50Á0-78Á5) for partial responders (Fig 2B) .
Outcome according to BCRi discontinuation
We evaluated by reason for BCRi discontinuation in the 86 patients exposed to a single BCRi (i.e. analysis excluding the dual BCRi exposed [n = 10], BCRi-na€ ıve patients [n = 6], the single patient on a blinded trial [n = 1] and those stopped to obtain a deeper response [n = 2]). The ORR to venetoclax in patients stopping a BCRi for toxicity was 92% (33/36; CR 22%; PR 69%) and for those with CLL progression on a BCRi was 84% (42/50; CR 28%; PR 56%; P = 0Á67). The PFS and OS were not statistically significantly different according to whether a patient had been exposed to a BTKi only, a PI3Ki only, or both. None of the BCRi-na€ ıve patients treated with venetoclax has experienced progression to date (Fig 3A,B) . For the whole cohort, those patients stopping BCRis for progression appeared to have an inferior PFS compared to patients stopping for reasons other than PD (toxicity n = 46; deeper response required n = 2), although this reached borderline statistical significance. In the 99 patients who were previously BCRi exposed, the risk of progression or death for patients stopping a prior BCRi for PD was double compared to those stopping for other reasons (predominantly toxicity) (hazard ratio [HR] 2Á01 [0Á99-4Á05], P = 0Á05) (Fig 3C) . Nine patients who received venetoclax as a therapeutic bridge to alloSCT all responded to venetoclax. All patients stopped venetoclax prior to alloSCT and did not restart venetoclax following engraftment. Two patients have died following alloSCT, both from infection at 7Á1 and 4Á7 months after stopping venetoclax. The remaining 7 patients all remain in remission at a median of 14Á6 (range 4Á4-17Á5) months following cessation of venetoclax.
Univariable and multivariable analyses
We wished to explore whether factors such as TP53 disruption, number of prior lines of therapy and ECOG PS were associated with survival outcomes following venetoclax. These factors were included alongside a series of additional baseline factors within a univariable and multivariable analysis of PFS and OS (Table SI and [1Á00-30Á70], P = 0Á0006) on univariable analysis. ECOG PS was the only factor that retained its significance for PFS on multivariable analysis (P = 0Á0026), however the number of events was still low. There was no significant difference in PFS (P = 0Á27) or OS (P = 0Á42) when patients with TP53-disrupted CLL were compared to TP53-intact CLL ( Figure S1A,B) . The number of prior treatment lines was significantly associated with PFS (HR compared to 1-2 lines: 2Á52 [1Á15-5Á51] for 3-4 lines, 2Á74 [1Á06-7Á12] for 5+ lines, P = 0Á017) within the univariable analysis (Figure S1C,D) . A similar effect was seen for OS (HR: 2Á37 [1Á03-5Á45] for 3-4 lines, 2Á24 [0Á81-6Á20] for 5+ lines, P = 0Á068) although this did not reach statistical significance. However, the number of prior treatment lines did not retain its significance for PFS on multivariable analysis (P = 0Á12). Age and male gender were significantly associated with inferior OS on multivariable analysis. Inferior OS was not observed in TP53-disrupted patients (HR disrupted vs non-disrupted: 1Á62 [0Á70-3Á72], P = 0Á34).
SII). Poorer baseline ECOG PS was associated with inferior PFS (HR compared to ECOG

Minimal residual disease
MRD was assessed by multi-colour flow cytometry on peripheral blood in 27% (28/105) after commencing venetoclax treatment. Of those assessed, 39% (11/28) had undetectable MRD (<10 À4 ) (7 patients in CR; 4 in PR) and 61% (17/28) were positive (2 CR; 15 PR). Eleven patients achieved undetectable MRD at a median of 8Á3 months (range 4Á5-10Á4) with 1 patient subsequently experiencing a clinical relapse 3Á7 months later. The other 10 MRD-negative patients have been followed for a median of 6Á8 months (range 3-23Á7) since achieving MRD negativity with no further clinical relapses at the time of database lock ( Figure S2A ).
AEs, venetoclax dose reductions and discontinuations
Venetoclax was generally well tolerated. During the course of venetoclax, 41% (43/105) patients had either a dose reduction or treatment interruption due to an AE. However, these patients were not more likely to discontinue venetoclax permanently due to an AE. In total, 8% (8/105) stopped venetoclax permanently due to toxicity (6Á5% [4/58] Figure S2B ,C). There were no treatment-related deaths. Overall, 43% (45/105) have stopped venetoclax. Discontinuation was most commonly due to PD (CLL; n = 14, Richter transformation (RT); n = 9). Nine patients stopped prior to alloSCT, 7 patients stopped due to toxicity, 5 due to death from unrelated causes (1 congestive cardiac failure [CCF] , 1 cerebrovascular accident [CVA] , 1 intracranial haemorrhage and 1 metastatic squamous cell carcinoma, 1 acute myeloid leukaemia [AML] ) and 1 due to frailty.
Unplanned hospital admissions whilst on venetoclax occurred in 42% (44/103) of cases (median 0 (range 0-6)). Reasons for the unplanned admissions are outlined in Table SIII . The dominant reason for admission was infection (22 episodes of infection non-otherwise specified, and 1 episode of neutropenic fever). There was 1 case of clinical TLS, 1 separate case of biochemical TLS and 1 case of isolated hyperphosphataemia. All 3 patients reached full dose and recovered with no clinical sequalae within the ramp-up phase.
To date, 33 patients have died in this cohort; 13 from PD of CLL, 10 from RT (1 B-PLL, 6 DLBCL, 1 unknown histology and 2 clinically suspected but not confirmed by histology), 3 from infection, and 7 from other causes (1 CVA, 1 CCF, 1 intracranial haemorrhage, 1 general frailty/poor nutrition, 1 metastatic squamous cell carcinoma, 2 AML).
Survival outcomes post progression
In total, 27 patients experienced PD due to CLL or RT on venetoclax. Five patients continued venetoclax beyond CLL PD with 2 patients still on venetoclax and 3 patients having subsequently died (1 CLL, 1 RT, 1 infection). Of the remaining 22 patients, 13 progressed with CLL and 9 with RT (1 patient also stopped venetoclax for toxicity and later developed RT). All patients with RT have died and 10/13 patients (A) (B) with CLL progression have died. Of all 27 patients with PD events on venetoclax, 5 remain alive with a median OS of 1Á5 months (95% CI 0Á4-8Á0 months) (Fig 4A,B) .
Of those that progressed with RT, 2 patients are known to have received further therapy. One patient received 2 cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) then 2 cycles of RGDP (rituximab, gemcitabine, dexamethasone, cisplatin) but failed to respond. The second patient received 3 cycles of RCHOP then 3 cycles of RGDP but failed to respond. Seven other RT patients received supportive palliative care and subsequent therapy was unknown in 1 patient. Of the 13 patients that progressed with CLL, 1 patient received palliative radiotherapy, 7 patients received best supportive care and subsequent therapy was unknown in 4 patients.
Discussion
We report on a large UK series of the earliest venetoclaxtreated R/R CLL patients outside of the clinical trial setting. Our cohort represents the majority of the patients treated within the early access schemes prior to formal venetoclax approval (105 patients of approximately 130). As is typical for early access schemes, patients were heavily pre-treated and had high-risk clinical features. The vast majority were BCRi exposed and almost half had evidence of TP53-disruption. Our dataset clearly demonstrates the efficacy of venetoclax monotherapy in routine practice for patients across a large and representative range of academic and non-academic centres with R/R, high-risk CLL with ORR, DOR and PFS comparable to clinical trial cohorts (Stilgenbauer et al, 2016; Jones et al, 2017; Coutre et al, 2018) and recently published US RWD (for example, 1-year PFS 65% compared to 1-year PFS 68% in US RWD) (Mato et al, 2018b) . Our data provide the first evidence in the non-trial setting of equivalent efficacy and survival in patients exposed to BTKi, PI3Ki or both classes of BCRi. Notably, and by contrast to recently published US RWD (Mato et al, 2018b) , we did not find significant differences in response or survival outcomes according to TP53 status. Consistent with a pooled analysis of 3 clinical trials of venetoclax monotherapy (Wierda et al, 2017b) , we demonstrate that more heavily pre-treated patients had an inferior PFS, although significance was not retained as an independent predictive factor in a multivariable analysis. In fact, the only characteristic that was significantly associated with inferior PFS in a multivariable model was ECOG PS. Twenty-eight percent had an ECOG PS >1 and thus would not have been eligible for the venetoclax clinical studies (Stilgenbauer et al, 2016; Jones et al, 2017; Coutre et al, 2018) . Clearly, ECOG PS is influenced by a range of patient and disease characteristics (for example, prior therapeutic lines and disease biology) although we could not find a clear statistical interaction between ECOG and TP53 status or prior lines of therapy (data not shown). However, the number of patients and events in the subgroups are relatively small so no strong conclusions can be drawn.
We provide further evidence of the safety and tolerability of venetoclax in the non-trial setting across a range of hospitals and demonstrate that dose attenuation and temporary treatment interruptions did not impact on PFS or OS. However, we cannot exclude survival bias within this specific analysis i.e. patients with superior survival may be more likely to have dose attenuation over time. Our reported rate of clinical and biochemical TLS is that which resulted in unplanned admission and, as such, the rate may differ compared to series reporting all cases of biochemical TLS. Notwithstanding this caveat, the TLS rate of 1% is consistent with that reported in clinical trials (Stilgenbauer et al, 2016; Davids et al, 2018) following the modifications to the dosing schedule to mitigate against TLS risk. The rate of TLS in our series is lower than the US RWD set. The reasons for this are not fully clear but may be related to risk assessment and prophylaxis strategies. We recognise the potential bias for under-reporting those cases without unplanned admission and misclassification according to the Howard criteria (Howard et al, 2011) . However, there was no demonstrable evidence concerning toxicities associated with TLS in our series.
By contrast to published non-clinical trial BCRi data, where toxicity was the most common reason for BCRi discontinuation (followed by CLL PD (Mato et al, 2018a) ), PD was the commonest reason for venetoclax discontinuation. These data are strikingly similar to results reported by Mato et al (2018b) (22/45 PD [CLL and RT] and 7/45 toxicity in the present UK series; 22/41 PD [CLL and RT] and 9/41 toxicity in the US series).
We provide the first evidence of a superior PFS for venetoclax-treated patients who discontinued BCRi for toxicity as compared to those who experienced progression on BCRi; the latter group of patients were twice as likely to progress or die following venetoclax compared to those failing BCRi for an alternative cause (predominantly toxicity) (HR 2Á01 [0Á99-4Á05] P = 0Á05). Consistent with data from clinical trials, we observed durable responses in patients obtaining CR and those achieving undetectable MRD in peripheral blood (including patients in PR). Although follow-up durations for both trial and non-trial cohorts are still relatively short, it seems likely that depth of response to venetoclax will translate into prolongation of PFS. Data such as these may be of particularly use when considering the role of consolidation therapy, for example alloSCT, in a selected, fit subgroup of R/R CLL patients obtaining responses on venetoclax. We also clearly demonstrate that patients who fail to respond to, or progress following, venetoclax have a dismal outcome with very limited survival. The unmet clinical need has therefore shifted to patients who fail both BCRi and venetoclax. Developing effective novel agents for such patients will prove challenging, not least because of the disease kinetics and short survival times but also because of the relatively high proportion of RT.
Our study has a number of limitations. Although our data were collected from representative UK centres, retrospective data collection is subject to the inherent biases of patient level data collection, AE reporting and response assessment. Recognising this, we attempted, where possible, to mitigate against such biases by applying established criteria and focusing on the most objective parameters. For example, we assigned reported 'clinical complete responses' (without bone marrow biopsy confirmation) as partial responses in line with iwCLL criteria. Similarly, we sought TLS data in line with established criteria. Moreover, we pragmatically limited our data collection to focus on routinely available clinical factors and simple venetoclax dosing information and thus did not request information on IGHV mutational status, cytogenetic information beyond TP53 status, or detailed information on maximum venetoclax dose reached and relative dose intensity. Consequently, we were able to achieve a near complete study database.
These limitations notwithstanding, our study details a large, multi-centre early experience of venetoclax in R/R CLL, demonstrating responses and survival outcomes consistent with published trials and US RWD. Importantly, we observed responses in patients exposed to either or both BTK and Pi3K inhibitor(s) and demonstrate, for the first time outside clinical trials, favourable clinical outcomes of patients obtaining CR and/or those achieving undetectable peripheral blood MRD. Patients with progression post-BCRi and venetoclax as sequential monotherapies remain a major challenge, but we look forward to emerging data from prospective trials investigating venetoclax in combination with BCRi and monoclonal antibody therapies (Hillmen et al, 2017; Seymour et al, 2018) . Combinatorial targeted approaches aimed at eradicating detectable MRD earlier in therapy are likely to impact favourably on how we approach CLL therapy in future.
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